4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

por Bartkowiak, Todd, Curran, Michael A.
Publicado 2015

Editorial: Advances in Combination Tumor Immunotherapy

por Curran, Michael A., Fox, Bernard A., Redmond, William L.
Publicado 2015

Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

por Curran, Michael A., Kim, Myoungjoo, Montalvo, Welby, Al-Shamkhani, Aymen, Allison, James P.
Publicado 2011

EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

por Kapp, Kerstin, Volz, Barbara, Curran, Michael A., Oswald, Detlef, Wittig, Burghardt, Schmidt, Manuel
Publicado 2019

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma

por Reilley, Matthew J., Morrow, Brittany, Ager, Casey R., Liu, Arthur, Hong, David S., Curran, Michael A.
Publicado 2019

Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer

por Jenq, Robert R., Curran, Michael A., Goldberg, Gabrielle L., Liu, Chen, Allison, James P., van den Brink, Marcel R. M.
Publicado 2012

Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma

por Gok Yavuz, Betul, Hasanov, Elshad, Lee, Sunyoung S, Mohamed, Yehia I, Curran, Michael A, Koay, Eugene J, Cristini, Vittorio, Kaseb, Ahmed O
Publicado 2021

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

por Curran, Michael A., Geiger, Theresa L., Montalvo, Welby, Kim, Myoungjoo, Reiner, Steven L., Al-Shamkhani, Aymen, Sun, Joseph C., Allison, James P.
Publicado 2013

Tumor hypoxia drives immune suppression and immunotherapy resistance

por Ai, Midan, Budhani, Pratha, Sheng, Jie, Balasubramanyam, Sadhana, Bartkowiak, Todd, Jaiswal, Ashvin R, Ager, Casey R, Haria, Dhwani D, Curran, Michael A
Publicado 2015

MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma

por de Azevedo, Ricardo A., Shoshan, Einav, Whang, Shanzhi, Markel, Gal, Jaiswal, Ashvin R., Liu, Arthur, Curran, Michael A., Travassos, Luiz R., Bar-Eli, Menashe
Publicado 2020

Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma

por Boudreau, C. Elizabeth, Najem, Hinda, Ott, Martina, Horbinski, Craig, Fang, Dexing, DeRay, Chase M., Levine, Jonathan M., Curran, Michael A., Heimberger, Amy B.
Publicado 2021

Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data

por Son, Ji, Hsieh, Rodney Cheng-En, Lin, Heather Y., Krause, Kate J., Yuan, Ying, Biter, Amadeo B., Welsh, James, Curran, Michael A., Hong, David S.
Publicado 2022

Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV(+) oral cancer

por Dorta-Estremera, Stephanie, Hegde, Venkatesh L., Slay, Ravaen B., Sun, Rachel, Yanamandra, Ananta V., Nicholas, Courtney, Nookala, Sita, Sierra, Gloria, Curran, Michael A., Sastry, K. Jagannadha
Publicado 2019

cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma

por Tripathi, Shashwat, Najem, Hinda, Mahajan, Akanksha Sanjay, Zhang, Peng, Low, Justin T, Stegh, Alexander H, Curran, Michael A, Ashley, David M, James, Charles David, Heimberger, Amy B
Publicado 2022

PD-1 blockade in combination with dasatinib potentiates induction of anti-acute lymphocytic leukemia immunity

por Koller, Paul, Baran, Natalia, Harutyunyan, Karine, Cavazos, Antonio, Mallampati, Saradhi, Chin, Renee L, Jiang, Zhou, Sun, Xian, Lee, Heng-Huan, Hsu, Jennifer L, Williams, Patrick, Huang, Xuelin, Curran, Michael A, Hung, Mien-Chie, Konopleva, Marina
Publicado 2023

High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege

por Ager, Casey R, Boda, Akash, Rajapakshe, Kimal, Lea, Spencer Thomas, Di Francesco, Maria Emilia, Jayaprakash, Priyamvada, Slay, Ravaen B, Morrow, Brittany, Prasad, Rishika, Dean, Meghan A, Duffy, Colm R, Coarfa, Cristian, Jones, Philip, Curran, Michael A
Publicado 2021

Peripheral and tumor immune correlates in patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) monotherapy or in combination with ipilimumab

por Postow, Michael A, Cardona, Diana M, Taube, Janis M, Anders, Robert A, Taylor, Clive R, Wolchok, Jedd D, Callahan, Margaret K, Curran, Michael A, Lesokhin, Alexander M, Grosso, Joseph F, Horak, Christine E, Cogswell, John, Simon, Jason S, Gupta, Ashok K, Sznol, Mario
Publicado 2014

Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain

por Singh, Manisha, Vianden, Christina, Cantwell, Mark J., Dai, Zhimin, Xiao, Zhilan, Sharma, Meenu, Khong, Hiep, Jaiswal, Ashvin R., Faak, Faisal, Hailemichael, Yared, Janssen, L. M. E., Bharadwaj, Uddalak, Curran, Michael A., Diab, Adi, Bassett, Roland L., Tweardy, David J., Hwu, Patrick, Overwijk, Willem W.
Publicado 2017

ISA101 and nivolumab for HPV-16(+) cancer: updated clinical efficacy and immune correlates of response

por de Sousa, Luana Guimaraes, Rajapakshe, Kimal, Rodriguez Canales, Jaime, Chin, Renee L, Feng, Lei, Wang, Qi, Barrese, Tomas Z, Massarelli, Erminia, William, William, Johnson, Faye M, Ferrarotto, Renata, Wistuba, Ignacio, Coarfa, Cristian, Lee, Jack, Wang, Jing, Melief, Cornelis J M, Curran, Michael A, Glisson, Bonnie S
Publicado 2022

Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models

por Sabbagh, Aria, Beccaria, Kevin, Ling, Xiaoyang, Marisetty, Anantha, Ott, Martina, Caruso, Hillary, Barton, Emily, Kong, Ling-Yuan, Fang, Dexing, Latha, Khatri, Zhang, Daniel Yang, Wei, Jun, DeGroot, John, Curran, Michael A., Rao, Ganesh, Hu, Jian, Desseaux, Carole, Bouchoux, Guillaume, Canney, Michael, Carpentier, Alexandre, Heimberger, Amy B.
Publicado 2021